Systematic review of dasatinib in chronic myeloid leukemia

OncoTargets and Therapy

Volumn 6, Issue , 2013, Pages 257-265

  Breccia, Massimo ^a   Salaroli, Adriano ^a   Molica, Matteo ^a   Alimena, Giuliana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Acute lymphoblastic leukemia; Chronic myeloid leukemia; Dasatinib

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DEXAMETHASONE; DOXORUBICIN; IMATINIB; METHOTREXATE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; ANEMIA; BLEEDING; BONE MARROW TRANSPLANTATION; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DEEP VEIN THROMBOSIS; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; EVENT FREE SURVIVAL; FATIGUE; FEBRILE NEUTROPENIA; FOLLOW UP; HUMAN; INFECTION; LEUKEMIA REMISSION; LEUKOPENIA; LUNG EMBOLISM; MAXIMUM TOLERATED DOSE; METABOLIC DISORDER; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHILADELPHIA CHROMOSOME POSITIVE CELL; PLEURA EFFUSION; PROGRESSION FREE SURVIVAL; REVIEW; STEM CELL TRANSPLANTATION; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84875693044     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S35360     Document Type: Review

References (35)

1. Keam SJ. Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Bio Drugs. 2008; 22(1):59-69.
2. Jabbour E, Cortes J, Kantarjian H. Dasatinib for the treatment of Philadelphia chromosome-positive leukemias. Expert Opin Investig Drugs. 2007;16(5):679-687.
3. Muller MC, Cortes JE, Kim DW, et al. Dasatinib treatment of chronic phase chronic myeloid leukemia: analysis of responses according to pre-existing BCR-ABL mutations.Blood.2009;114(24): 4944-4953.
4. Shah NP. Dasatinib. Drugs Today (Barc). 2007;43(1):5-12.
5. Nam S, Williams A, Vultur A, et al. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Mol Cancer Ther. 2007;6(4):1400-1405.
6. Steinberg M. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. Clin Ther. 2007;29(11):2289-2308.
7. Minematsu T, Giacomini KM. Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. Mol Cancer Ther. 2011;10(3):531-539.
8. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006; 354(24):2531-2541.
9. Cortes J, Sawyers CL, Kantarjian H, et al. Long-term efficacy of dasatinib in chronic phase CML: results from the phase I trial (CA180002). Blood. 2007;110:1026.
10. Hochhaus A, Kantarjian H, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007;110(5): 2303-2309.
11. Branford S, Hochhaus A, Mueller M, et al. Analysis of molecular data and the emergence of mutations for chronic-phase chronic myelogenous leukemia (CML-CP) patients treated with dasatinib after imatinib failure. Blood. 2009;114:3282.
12. Hochhaus A, Baccarani M, Deiniger M, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008;22(6):1200-1206.
13. Kantarjian H, Pasquini R, Levy V, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer. 2009;115(18):3935-3943.
14. Apperley JF, Cortes JE, Kim DW, et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START trial. J Clin Oncol. 2009;27(21):3472-3479.
15. Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or intolerant chronic myeloid leukemia in blast crisis. Blood. 2007; 109(8):3207-3213.
16. Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood. 2007; 110(7):2309-2315.
17. Shah NP, Kim DW, Kantarjian H, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica. 2010;95(2):232-240.
18. Rea D, Vellenga E, Junghan C, et al. Six-year follow-up of patients with imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia (CML-CP) receiving dasatinib. Haematologica. 2012; 97 Suppl 1:199.
19. Pemmaraju N, Kantarjian H, Luthra R, et al. Results of a phase II trial of dasatinib as frontline therapy for chronic myeloid leukemia (CML) in chronic phase. Blood. 2011;118:1700.
20. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260-2270.
21. Giles F, Mahon FX, Gjertsen B, et al. Developmental therapeutics consortium report on study design effects on trial outcomes in chronic myeloid leukemia. Eur J Clin Invest. 2012;42(9):1016-1026.
22. Pinilla-Ibarz J, Flinn I. The expanding options for front-line treatment in patients with newly diagnosed CML. Crit Rev Oncol Hematol. 2012; 84(2):287-299.
23. Thienelt CD, Green K, Bowles DW. New and established tyrosine kinase inhibitors for chronic myeloid leukemia. Drugs Today (Barc). 2012; 48(9):601-613.
24. Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012;119(5): 1123-1129.
25. Breccia M, Efficace F, Alimena G. Progressive arterial occlusive disease (PAOD) and pulmonary arterial hypertension (PAH) as new adverse events of second generation TKIs in CML treatment: who's afraid of the big bad wolf? Leuk Res. 2012;36(7):813-814.
26. Montani D, Bergot E, Gunther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125(17):2128-2137.
27. Hochhaus A, Boque C, Garelik B, et al. Molecular response kinetics and bcr-abl reductions in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) receiving dasatinib vs imatinib: DASISION 3-years follow-up. Haematologica. 2012;97 Suppl 1:192.
28. Radich JP, Kopecky KJ, Appelbaum FR, et al. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood. 2012;120(19):3898-3905.
29. Ravandi F, O'Brien S, Thomas D, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood. 2010;116(12):2070-2077.
30. Foa R, Vitale A, Vignetti M, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011;118(25):6521-6528.
31. Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006;107(11):4532-4539.
32. Konig H, Copland M, Chu S, et al. Effects of dasatinib on SRC kinase activity and downstream intracellular signalling in primitive chronic myelogenous leukemia hematopoietic cells. Cancer Res. 2008;68(23): 9624-9633.
33. Copland M, Pellicano F, Richmond L, et al. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood. 2008; 111(85):2843-2853.
34. Bellodi C, Lidonnici MR, Hamilton A, et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest. 2009;119(5):1109-1123.
35. Goff DJ, Recart AC, Sadarangani A, et al. A pan BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell. January 15, 2013. [Epub ahead of print.]